PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
34647453-6	2021	Further, we found that this ceramide accumulation on LPs was orchestrated by ceramide synthase 2, inhibition of which hampers phagosomal maturation.	Ceramides	28-36	ceramide synthase 2	Homo sapiens	77-96
34915026-6	2022	In addition, lipidomics analyses by HPLC-MS/MS showed bias towards CerS2-associated C20:0/C20:1-ceramides compared to CerS5/6-associated C14:0/C16:0-ceramides (2:1).	1-ceramides	94-105	ceramide synthase 2	Homo sapiens	67-72
34915026-9	2022	Additionally, downregulation of CerS2/6, but not CerS5, attenuated ABCB1 mRNA, protein, plasma membrane localization, rhodamine 123+ efflux transport activity, and doxorubicin resistance.	Rhodamine 123	118-131	ceramide synthase 2	Homo sapiens	32-39
34915026-9	2022	Additionally, downregulation of CerS2/6, but not CerS5, attenuated ABCB1 mRNA, protein, plasma membrane localization, rhodamine 123+ efflux transport activity, and doxorubicin resistance.	Doxorubicin	164-175	ceramide synthase 2	Homo sapiens	32-39
34915026-12	2022	Inhibitors of ER-associated degradation (ERAD) (eeyarestatin I) and the proteasome (MG132, bortezomib) prevented ABCB1 loss induced by CerS2/6 downregulation.	1-(4-chlorophenyl)-3-(3-(4-chlorophenyl)-5,5-dimethyl-1-(3-(5-nitrofuran-2-yl)allyldienehydrazinocarbonylmethyl)-2-oxoimidazolidin-4-yl)-1-hydroxyurea	48-62	ceramide synthase 2	Homo sapiens	135-140
34915026-12	2022	Inhibitors of ER-associated degradation (ERAD) (eeyarestatin I) and the proteasome (MG132, bortezomib) prevented ABCB1 loss induced by CerS2/6 downregulation.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	84-89	ceramide synthase 2	Homo sapiens	135-140
34915026-12	2022	Inhibitors of ER-associated degradation (ERAD) (eeyarestatin I) and the proteasome (MG132, bortezomib) prevented ABCB1 loss induced by CerS2/6 downregulation.	Bortezomib	91-101	ceramide synthase 2	Homo sapiens	135-140
34769283-11	2021	Dox and CerS2 overexpression increased CerS2 protein expression.	Doxorubicin	0-3	ceramide synthase 2	Homo sapiens	39-44
34400330-0	2022	Silencing of ceramide synthase 2 in hepatocytes modulates plasma ceramide biomarkers predictive of cardiovascular death.	Ceramides	65-73	ceramide synthase 2	Homo sapiens	13-32
34400330-3	2022	Here, we outline the development of a potent N-acetylgalactosamine-conjugated antisense oligonucleotide engineered to silence ceramide synthase 2 specifically in hepatocytes in vivo.	Acetylgalactosamine	45-66	ceramide synthase 2	Homo sapiens	126-145
34400330-3	2022	Here, we outline the development of a potent N-acetylgalactosamine-conjugated antisense oligonucleotide engineered to silence ceramide synthase 2 specifically in hepatocytes in vivo.	Oligonucleotides	88-103	ceramide synthase 2	Homo sapiens	126-145
34361066-6	2021	Importantly, PS selectively increases ceramides with long-chain fatty acids (FAs) (C22-C24), which mainly account for the formation of the epidermal barrier, through activation of ceramide synthase (CerS) 2 and Cer3 in IL-4-mediated inflamed KC.	N-palmitoylserinol	13-15	ceramide synthase 2	Homo sapiens	180-206
35626132-7	2022	Here, we further clarified that treatment with C2-ceramide alone increases the protein level of CERS2, which modulates sphingolipid metabolism to favor the conversion of C2-ceramide to prosurvival sphingolipids in HCC cells, thus activating the unfolded protein response (UPR), which further initiates autophagy and the reversible senescence-like phenotype (SLP), ultimately contributing to C2-ceramide resistance in these cells.	N-acetylsphingosine	47-58	ceramide synthase 2	Homo sapiens	96-101
35626132-7	2022	Here, we further clarified that treatment with C2-ceramide alone increases the protein level of CERS2, which modulates sphingolipid metabolism to favor the conversion of C2-ceramide to prosurvival sphingolipids in HCC cells, thus activating the unfolded protein response (UPR), which further initiates autophagy and the reversible senescence-like phenotype (SLP), ultimately contributing to C2-ceramide resistance in these cells.	N-acetylsphingosine	170-181	ceramide synthase 2	Homo sapiens	96-101
35626132-7	2022	Here, we further clarified that treatment with C2-ceramide alone increases the protein level of CERS2, which modulates sphingolipid metabolism to favor the conversion of C2-ceramide to prosurvival sphingolipids in HCC cells, thus activating the unfolded protein response (UPR), which further initiates autophagy and the reversible senescence-like phenotype (SLP), ultimately contributing to C2-ceramide resistance in these cells.	Sphingolipids	197-210	ceramide synthase 2	Homo sapiens	96-101
35626132-7	2022	Here, we further clarified that treatment with C2-ceramide alone increases the protein level of CERS2, which modulates sphingolipid metabolism to favor the conversion of C2-ceramide to prosurvival sphingolipids in HCC cells, thus activating the unfolded protein response (UPR), which further initiates autophagy and the reversible senescence-like phenotype (SLP), ultimately contributing to C2-ceramide resistance in these cells.	N-acetylsphingosine	391-402	ceramide synthase 2	Homo sapiens	96-101
35626132-8	2022	However, cotreatment with diTFPP and ceramide downregulated the protein level of CERS2 and increased oxidative and endoplasmic reticulum (ER) stress.	ditfpp	26-32	ceramide synthase 2	Homo sapiens	81-86
35626132-8	2022	However, cotreatment with diTFPP and ceramide downregulated the protein level of CERS2 and increased oxidative and endoplasmic reticulum (ER) stress.	Ceramides	37-45	ceramide synthase 2	Homo sapiens	81-86
35169703-12	2022	The expression of ceramide synthase 2, which synthesizes very-long-chain sphingolipids, was not different in Huntington"s brain.	Sphingolipids	73-86	ceramide synthase 2	Homo sapiens	18-37
35169703-14	2022	Post-translational modifications to ceramide synthase 2 may be driving the distinctive sphingolipid profile shifts of the caudate in advanced Huntington"s disease.	Sphingolipids	87-99	ceramide synthase 2	Homo sapiens	36-55
33852174-1	2021	LASS2 is a novel tumor-suppressor gene and has been characterized as a ceramide synthase, which synthesizes very-long acyl chain ceramides.	Ceramides	129-138	ceramide synthase 2	Homo sapiens	0-5
33852174-3	2021	Here, we firstly report that LASS2 promotes beta-catenin degradation through physical interaction with STK38, SCYL2, and ATP6V0C via the ubiquitin-proteasome pathway, phosphorylation of LASS2 is essential for beta-catenin degradation, and serine residue 248 of LASS2 is illustrated to be a key phosphorylation site.	Serine	239-245	ceramide synthase 2	Homo sapiens	29-34
33852174-3	2021	Here, we firstly report that LASS2 promotes beta-catenin degradation through physical interaction with STK38, SCYL2, and ATP6V0C via the ubiquitin-proteasome pathway, phosphorylation of LASS2 is essential for beta-catenin degradation, and serine residue 248 of LASS2 is illustrated to be a key phosphorylation site.	Serine	239-245	ceramide synthase 2	Homo sapiens	186-191
33852174-3	2021	Here, we firstly report that LASS2 promotes beta-catenin degradation through physical interaction with STK38, SCYL2, and ATP6V0C via the ubiquitin-proteasome pathway, phosphorylation of LASS2 is essential for beta-catenin degradation, and serine residue 248 of LASS2 is illustrated to be a key phosphorylation site.	Serine	239-245	ceramide synthase 2	Homo sapiens	186-191
33852174-4	2021	Furthermore, we find that dephosphorylation of LASS2 at serine residue 248 significantly enhances prostate cancer cell growth and metastasis in vivo, indicating that phosphorylated LASS2 inhibits prostate carcinogenesis through negative regulation of Wnt/beta-catenin signaling.	Serine	56-62	ceramide synthase 2	Homo sapiens	47-52
33884288-0	2021	Alternative splicing of CERS2 promotes cell proliferation and migration in luminal B subtype breast cancer cells.	Phenobarbital	75-82	ceramide synthase 2	Homo sapiens	24-29
33841656-15	2021	In addition, metformin overcame progestin resistance by down-regulating Nrf2/LASS2 expression.	Metformin	13-22	ceramide synthase 2	Homo sapiens	77-82
33568634-0	2021	Alternative splicing of ceramide synthase 2 alters levels of specific ceramides and modulates cancer cell proliferation and migration in Luminal B breast cancer subtype.	Ceramides	70-79	ceramide synthase 2	Homo sapiens	24-43
33568634-3	2021	We show that ceramide synthase 2 (CERS2) undergoes a unique cassette exon event specifically in Luminal B subtype tumors.	Phenobarbital	96-103	ceramide synthase 2	Homo sapiens	13-32
33568634-3	2021	We show that ceramide synthase 2 (CERS2) undergoes a unique cassette exon event specifically in Luminal B subtype tumors.	Phenobarbital	96-103	ceramide synthase 2	Homo sapiens	34-39
33568634-5	2021	Differential AS-based survival analysis shows that this AS event of CERS2 is a poor prognostic factor for Luminal B patients.	Phenobarbital	106-113	ceramide synthase 2	Homo sapiens	68-73
33568634-6	2021	As Exon 8 corresponds to catalytic Lag1p domain, overexpression of AS transcript of CERS2 in Luminal B cancer cells leads to a reduction in the level of very-long-chain ceramides compared to overexpression of protein-coding (PC) transcript of CERS2.	Phenobarbital	93-100	ceramide synthase 2	Homo sapiens	84-89
33568634-6	2021	As Exon 8 corresponds to catalytic Lag1p domain, overexpression of AS transcript of CERS2 in Luminal B cancer cells leads to a reduction in the level of very-long-chain ceramides compared to overexpression of protein-coding (PC) transcript of CERS2.	Phenobarbital	93-100	ceramide synthase 2	Homo sapiens	243-248
33423335-0	2021	Ceramide synthase 2-C24:1 -ceramide axis limits the metastatic potential of ovarian cancer cells.	1 -ceramide	24-35	ceramide synthase 2	Homo sapiens	0-19
33423335-11	2021	These results suggested that C24:1 -ceramide, a CerS2 metabolite, predominantly suppresses the formation of lamellipodia without the requirement for deacylation/reacylation.	c24:1 -ceramide	29-44	ceramide synthase 2	Homo sapiens	48-53
33423335-13	2021	Collectively, the CerS2-C24:1 -ceramide axis, which may be countered by neutral ceramidase, is suggested to limit cell motility and metastatic potential.	1 -ceramide	28-39	ceramide synthase 2	Homo sapiens	18-23
32374916-4	2021	In present study, we revealed aberrant gene expressions (e.g. SPTLC1 and CERS2) of de novo ceramide biosynthesis and length-specific ceramide production in GBC tissues.	Ceramides	91-99	ceramide synthase 2	Homo sapiens	73-78
32374916-4	2021	In present study, we revealed aberrant gene expressions (e.g. SPTLC1 and CERS2) of de novo ceramide biosynthesis and length-specific ceramide production in GBC tissues.	Ceramides	133-141	ceramide synthase 2	Homo sapiens	73-78
33515546-3	2021	In many cell types, CerS2, which catalyzes the synthesis of very long chain ceramides, is the major CerS.	Ceramides	76-85	ceramide synthase 2	Homo sapiens	20-25
33515546-5	2021	As expected, we observed that very long chain ceramide, hexosylceramide, and sphingomyelin were reduced in CerS2 knockout cells.	Ceramides	46-54	ceramide synthase 2	Homo sapiens	107-112
33515546-5	2021	As expected, we observed that very long chain ceramide, hexosylceramide, and sphingomyelin were reduced in CerS2 knockout cells.	hexosylceramide	56-71	ceramide synthase 2	Homo sapiens	107-112
33515546-5	2021	As expected, we observed that very long chain ceramide, hexosylceramide, and sphingomyelin were reduced in CerS2 knockout cells.	Sphingomyelins	77-90	ceramide synthase 2	Homo sapiens	107-112
33414460-0	2021	Targeting sphingosine kinase 1 (SK1) enhances oncogene-induced senescence through ceramide synthase 2 (CerS2)-mediated generation of very-long-chain ceramides.	Ceramides	149-158	ceramide synthase 2	Homo sapiens	82-101
33414460-0	2021	Targeting sphingosine kinase 1 (SK1) enhances oncogene-induced senescence through ceramide synthase 2 (CerS2)-mediated generation of very-long-chain ceramides.	Ceramides	149-158	ceramide synthase 2	Homo sapiens	103-108
32356173-3	2020	At 3 months of age AbetaPP/Abeta presence upregulated enzymes of ceramide turnover on the salvage pathway: ceramide synthases (CERS2, CERS4, CERS6) and also ceramidase ACER3.	Ceramides	65-73	ceramide synthase 2	Homo sapiens	127-132
32356173-8	2020	Fingolimod (FTY720), a modulator of sphingosine-1-phosphate receptors countered the AbetaPP-dependent upregulation of hippocampal ceramide synthase CERS2 at 3 months.	Fingolimod Hydrochloride	0-10	ceramide synthase 2	Homo sapiens	148-153
32356173-8	2020	Fingolimod (FTY720), a modulator of sphingosine-1-phosphate receptors countered the AbetaPP-dependent upregulation of hippocampal ceramide synthase CERS2 at 3 months.	Fingolimod Hydrochloride	12-18	ceramide synthase 2	Homo sapiens	148-153
32356173-8	2020	Fingolimod (FTY720), a modulator of sphingosine-1-phosphate receptors countered the AbetaPP-dependent upregulation of hippocampal ceramide synthase CERS2 at 3 months.	sphingosine 1-phosphate	36-59	ceramide synthase 2	Homo sapiens	148-153
31785811-5	2020	Silencing and overexpression of CerS C4M4U4 (the closest homolog of human CerS 2 and 3) demonstrated its involvement in the synthesis of ceramide.	Ceramides	137-145	ceramide synthase 2	Homo sapiens	74-86
31544710-5	2020	RESULTS: HCC is characterised by dysregulation of ceramide metabolism, which could be ascribed to altered activity and expression of ceramide synthases 2, 4 and 6, and acid and alkaline ceramidases 2 and 3, as well as to deregulation of sphingosine kinases (SphK) 1 and 2 and sphingosine-1-phosphate receptors, in particular S1PR1.	Ceramides	50-58	ceramide synthase 2	Homo sapiens	133-162
30896811-5	2019	It was determined that the overexpression of LASS2 inhibited HepG2 cell viability and proliferation, as determined by cell counting kit-8 and colony formation assays, and induced apoptosis by increasing reactive oxygen species, reducing mitochondrial membrane potential and inducing intracellular Ca2+ overload.	Reactive Oxygen Species	203-226	ceramide synthase 2	Homo sapiens	45-50
30996356-8	2019	MTT test and growth curve assay showed growth ability in LASS2/TMSG1 S248A group was increasing compared with other groups from day 5.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	57-62
30996356-8	2019	MTT test and growth curve assay showed growth ability in LASS2/TMSG1 S248A group was increasing compared with other groups from day 5.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	63-68
30251650-7	2018	We also found that the FA elongase ELOVL1 and the ceramide synthase CERS2 were involved in C24:2 ceramide production.	Ceramides	50-58	ceramide synthase 2	Homo sapiens	68-73
30059758-6	2018	By contrast, in the p53-deficient cells CerS2 expression and CerS2-related C24:0- and C24:1-ceramide levels were elevated which is possibly related to enhanced polyadenylation of the CerS2 transcript in these cells.	Ceramides	92-100	ceramide synthase 2	Homo sapiens	61-66
30059758-6	2018	By contrast, in the p53-deficient cells CerS2 expression and CerS2-related C24:0- and C24:1-ceramide levels were elevated which is possibly related to enhanced polyadenylation of the CerS2 transcript in these cells.	Ceramides	92-100	ceramide synthase 2	Homo sapiens	61-66
29632068-7	2018	Moreover, a chimeric protein, CerS4(291-301 CerS2), based on CerS4 (which normally generates C18-C22 ceramides) displayed significant activity toward C24:1-CoA.	Ceramides	101-110	ceramide synthase 2	Homo sapiens	44-49
29581781-12	2018	ERK inhibitor PD98059 suppressed Drp1 phosphorylation and abrogated the effects of LASS2 depletion.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	14-21	ceramide synthase 2	Homo sapiens	83-88
28356943-5	2017	Silencing of LASS2 in RT4 cells was able to increase V-ATPase activity, the extracellular hydrogen ion concentration and, in turn, the activation of secreted matrix metalloproteinase (MMP)-2 and MMP-9, which occurred simultaneously with enhanced cell proliferation, cell survival and cell invasion in vitro, as well as acceleration of BC growth in vivo.	Hydrogen	90-98	ceramide synthase 2	Homo sapiens	13-18
28356943-6	2017	In this process, it was found that siRNA-LASS2 treatment was able to suppress cell apoptosis induced by doxorubicin.	Doxorubicin	104-115	ceramide synthase 2	Homo sapiens	41-46
27775668-2	2016	Ceramide synthase 2 (CERS2), one of the six ceramide synthase isoforms, is responsible for the synthesis of very long chain fatty acid (C20-26 fatty acids) (VLC)-containing ceramides (VLC-Cer).	long	113-117	ceramide synthase 2	Homo sapiens	0-19
27775668-2	2016	Ceramide synthase 2 (CERS2), one of the six ceramide synthase isoforms, is responsible for the synthesis of very long chain fatty acid (C20-26 fatty acids) (VLC)-containing ceramides (VLC-Cer).	long	113-117	ceramide synthase 2	Homo sapiens	21-26
27775668-2	2016	Ceramide synthase 2 (CERS2), one of the six ceramide synthase isoforms, is responsible for the synthesis of very long chain fatty acid (C20-26 fatty acids) (VLC)-containing ceramides (VLC-Cer).	chain fatty acid	118-134	ceramide synthase 2	Homo sapiens	0-19
27775668-2	2016	Ceramide synthase 2 (CERS2), one of the six ceramide synthase isoforms, is responsible for the synthesis of very long chain fatty acid (C20-26 fatty acids) (VLC)-containing ceramides (VLC-Cer).	chain fatty acid	118-134	ceramide synthase 2	Homo sapiens	21-26
27775668-2	2016	Ceramide synthase 2 (CERS2), one of the six ceramide synthase isoforms, is responsible for the synthesis of very long chain fatty acid (C20-26 fatty acids) (VLC)-containing ceramides (VLC-Cer).	c20-26 fatty acids	136-154	ceramide synthase 2	Homo sapiens	0-19
27775668-2	2016	Ceramide synthase 2 (CERS2), one of the six ceramide synthase isoforms, is responsible for the synthesis of very long chain fatty acid (C20-26 fatty acids) (VLC)-containing ceramides (VLC-Cer).	c20-26 fatty acids	136-154	ceramide synthase 2	Homo sapiens	21-26
27775668-2	2016	Ceramide synthase 2 (CERS2), one of the six ceramide synthase isoforms, is responsible for the synthesis of very long chain fatty acid (C20-26 fatty acids) (VLC)-containing ceramides (VLC-Cer).	Ceramides	173-182	ceramide synthase 2	Homo sapiens	0-19
27775668-2	2016	Ceramide synthase 2 (CERS2), one of the six ceramide synthase isoforms, is responsible for the synthesis of very long chain fatty acid (C20-26 fatty acids) (VLC)-containing ceramides (VLC-Cer).	Ceramides	173-182	ceramide synthase 2	Homo sapiens	21-26
27775668-5	2016	VLC-sphingolipid expression was increased along with that of CERS2, and the proportion of VLC species in glucosylceramide (GlcCer) was higher than that in SM for all expression levels of CERS2.	Glucosylceramides	105-121	ceramide synthase 2	Homo sapiens	187-192
27775668-5	2016	VLC-sphingolipid expression was increased along with that of CERS2, and the proportion of VLC species in glucosylceramide (GlcCer) was higher than that in SM for all expression levels of CERS2.	Glucosylceramides	123-129	ceramide synthase 2	Homo sapiens	187-192
27255818-4	2016	The synthesis of very long chain ceramides is catalyzed by ceramide synthase 2 (CERS2).	Ceramides	33-42	ceramide synthase 2	Homo sapiens	59-78
27255818-4	2016	The synthesis of very long chain ceramides is catalyzed by ceramide synthase 2 (CERS2).	Ceramides	33-42	ceramide synthase 2	Homo sapiens	80-85
26398595-11	2015	These observations were demonstrated by suppression of CerS2 using siRNA in HepG2 cells; that is, siRNA for CerS2 specifically decreased C22 very long-chain fatty acid (VLCFA)- and C24 VLCFA-containing SMs.	c22 very long-chain fatty acid	137-167	ceramide synthase 2	Homo sapiens	55-60
26398595-11	2015	These observations were demonstrated by suppression of CerS2 using siRNA in HepG2 cells; that is, siRNA for CerS2 specifically decreased C22 very long-chain fatty acid (VLCFA)- and C24 VLCFA-containing SMs.	c22 very long-chain fatty acid	137-167	ceramide synthase 2	Homo sapiens	108-113
26528430-10	2015	Sphingolipid genes for ceramide synthases 2 and 6 (CerS2; CerS6), delta(4)-desaturase sphingolipid 2 (DEGS2), and acidic sphingomyelinase (SMPD1) displayed higher expression levels in breast cancer vs. control tissue, whereas ceramide galactosyltransferase (UGT8) was underexpressed in breast cancer samples.	Sphingolipids	0-12	ceramide synthase 2	Homo sapiens	23-49
26528430-10	2015	Sphingolipid genes for ceramide synthases 2 and 6 (CerS2; CerS6), delta(4)-desaturase sphingolipid 2 (DEGS2), and acidic sphingomyelinase (SMPD1) displayed higher expression levels in breast cancer vs. control tissue, whereas ceramide galactosyltransferase (UGT8) was underexpressed in breast cancer samples.	Sphingolipids	0-12	ceramide synthase 2	Homo sapiens	51-56
26113602-3	2015	CerS2, one of six mammalian CerS, synthesizes ceramides with very-long (C22-C24) chains.	Ceramides	46-55	ceramide synthase 2	Homo sapiens	0-5
25735224-5	2015	MTT assays showed that overexpression of TMSG1/LASS2 inhibited cell proliferation; and morphological observations and flow cytometric assays with Annexin V/propidium iodide showed TMSG1/LASS2 overexpression increased apoptosis in these cells.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	41-46
25735224-5	2015	MTT assays showed that overexpression of TMSG1/LASS2 inhibited cell proliferation; and morphological observations and flow cytometric assays with Annexin V/propidium iodide showed TMSG1/LASS2 overexpression increased apoptosis in these cells.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	47-52
25735224-5	2015	MTT assays showed that overexpression of TMSG1/LASS2 inhibited cell proliferation; and morphological observations and flow cytometric assays with Annexin V/propidium iodide showed TMSG1/LASS2 overexpression increased apoptosis in these cells.	Propidium	156-172	ceramide synthase 2	Homo sapiens	41-46
25735224-5	2015	MTT assays showed that overexpression of TMSG1/LASS2 inhibited cell proliferation; and morphological observations and flow cytometric assays with Annexin V/propidium iodide showed TMSG1/LASS2 overexpression increased apoptosis in these cells.	Propidium	156-172	ceramide synthase 2	Homo sapiens	180-185
25735224-5	2015	MTT assays showed that overexpression of TMSG1/LASS2 inhibited cell proliferation; and morphological observations and flow cytometric assays with Annexin V/propidium iodide showed TMSG1/LASS2 overexpression increased apoptosis in these cells.	Propidium	156-172	ceramide synthase 2	Homo sapiens	186-191
25975960-5	2015	Levels of two enzymes participating in the biosynthesis and degradation of AEA, N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NPLD) and fatty acid amide hydrolase (FAAH), together with the most abundant ceramide synthases (CerS1, CerS2, CerS5 and CerS6) in the colon were also determined.	aea	75-78	ceramide synthase 2	Homo sapiens	245-250
25697397-2	2015	In experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), we observed a significant elevation of CerS2 and its products, C24-ceramides, in CD11b(+) cells (monocytes and neutrophils) isolated from blood.	c24-ceramides	159-172	ceramide synthase 2	Homo sapiens	135-140
25213553-9	2015	Taken together, CERS2 can significantly inhibit breast cancer cell invasion and is associated with the decrease of the V-ATPase activity and extracellular hydrogen ion concentration, and in turn the activation of secreted MMP-2/MMP-9 and degradation of extracellular matrix (ECM), which ultimately suppressed tumor"s invasion.	Hydrogen	155-163	ceramide synthase 2	Homo sapiens	16-21
25501280-4	2015	PcDNA3 eukaryotic expression plasmids of LASS2/TMSG1 were constructed and transfected into human breast cancer cell line MCF-7 by lipofectin transfection method.	1,2-dielaidoylphosphatidylethanolamine	130-140	ceramide synthase 2	Homo sapiens	41-46
25501280-8	2015	Therefore, LASS2/TMSG1 may inhibit growth and invasion of breast cancer cell in vitro through decreasing V-ATPase activity and extracellular hydrogen ion concentration and inactivating secreted MMP-2.	Hydrogen	141-149	ceramide synthase 2	Homo sapiens	11-16
25501280-8	2015	Therefore, LASS2/TMSG1 may inhibit growth and invasion of breast cancer cell in vitro through decreasing V-ATPase activity and extracellular hydrogen ion concentration and inactivating secreted MMP-2.	Hydrogen	141-149	ceramide synthase 2	Homo sapiens	17-22
25403920-10	2015	Using this approach, we show that CERS2 demonstrates a preference for the monounsaturated C24:1 fatty acid substrate compared to the saturated C24:0 substrate, potentially explaining why myelin is enriched in ceramides containing the monounsaturated form of very long chain fatty acids.	Fatty Acids	96-106	ceramide synthase 2	Homo sapiens	34-39
25403920-10	2015	Using this approach, we show that CERS2 demonstrates a preference for the monounsaturated C24:1 fatty acid substrate compared to the saturated C24:0 substrate, potentially explaining why myelin is enriched in ceramides containing the monounsaturated form of very long chain fatty acids.	Ceramides	209-218	ceramide synthase 2	Homo sapiens	34-39
25403920-10	2015	Using this approach, we show that CERS2 demonstrates a preference for the monounsaturated C24:1 fatty acid substrate compared to the saturated C24:0 substrate, potentially explaining why myelin is enriched in ceramides containing the monounsaturated form of very long chain fatty acids.	chain fatty acids	268-285	ceramide synthase 2	Homo sapiens	34-39
25451689-4	2014	Only the activities of CerS4 and CerS5 promoter Luc constructs, as well as CerS2- and CerS5-3"-UTR Luc constructs increased after estradiol treatment in MCF-7 cells, and this could be inhibited by the anti-estrogen fulvestrant.	Estradiol	130-139	ceramide synthase 2	Homo sapiens	75-80
25267995-8	2014	CerS2 deletion resulted in bulk loss of sulfatides with C23/C24-acyl chains, but did not lead to decreased urinary pH, as previously observed in sulfatide-depleted kidneys.	Sulfoglycosphingolipids	40-50	ceramide synthase 2	Homo sapiens	0-5
25267995-8	2014	CerS2 deletion resulted in bulk loss of sulfatides with C23/C24-acyl chains, but did not lead to decreased urinary pH, as previously observed in sulfatide-depleted kidneys.	Sulfoglycosphingolipids	40-49	ceramide synthase 2	Homo sapiens	0-5
25295789-3	2014	Haploinsufficiency for ceramide synthase 2 (CerS2), the dominant isoform in the liver that preferentially makes very-long-chain (C22/C24/C24:1) ceramides, led to compensatory increases in long-chain C16-ceramides and conferred susceptibility to diet-induced steatohepatitis and insulin resistance.	Ceramides	144-153	ceramide synthase 2	Homo sapiens	23-42
25295789-3	2014	Haploinsufficiency for ceramide synthase 2 (CerS2), the dominant isoform in the liver that preferentially makes very-long-chain (C22/C24/C24:1) ceramides, led to compensatory increases in long-chain C16-ceramides and conferred susceptibility to diet-induced steatohepatitis and insulin resistance.	Ceramides	144-153	ceramide synthase 2	Homo sapiens	44-49
25295789-3	2014	Haploinsufficiency for ceramide synthase 2 (CerS2), the dominant isoform in the liver that preferentially makes very-long-chain (C22/C24/C24:1) ceramides, led to compensatory increases in long-chain C16-ceramides and conferred susceptibility to diet-induced steatohepatitis and insulin resistance.	N-palmitoylsphingosine	199-212	ceramide synthase 2	Homo sapiens	23-42
25295789-3	2014	Haploinsufficiency for ceramide synthase 2 (CerS2), the dominant isoform in the liver that preferentially makes very-long-chain (C22/C24/C24:1) ceramides, led to compensatory increases in long-chain C16-ceramides and conferred susceptibility to diet-induced steatohepatitis and insulin resistance.	N-palmitoylsphingosine	199-212	ceramide synthase 2	Homo sapiens	44-49
25295789-5	2014	Inhibiting global ceramide synthesis negated the effects of CerS2 haploinsufficiency in vivo, and increasing C16-ceramides by overexpressing CerS6 recapitulated the phenotype in isolated, primary hepatocytes.	Ceramides	18-26	ceramide synthase 2	Homo sapiens	60-65
24453046-5	2014	Silencing of LASS2/TMSG1 gene in PC-3M-2B4 cells increased V-ATPase activity, extracellular hydrogen ion concentration and in turn the activation of secreted MMP-2 and MMP-9, which coincided with enhancing cell proliferation, cell survival, and cell invasion in vitro, as well as acceleration of prostate cancer (PCA) growth and lymph node metastases in vivo.	Hydrogen	92-100	ceramide synthase 2	Homo sapiens	13-18
24453046-5	2014	Silencing of LASS2/TMSG1 gene in PC-3M-2B4 cells increased V-ATPase activity, extracellular hydrogen ion concentration and in turn the activation of secreted MMP-2 and MMP-9, which coincided with enhancing cell proliferation, cell survival, and cell invasion in vitro, as well as acceleration of prostate cancer (PCA) growth and lymph node metastases in vivo.	Hydrogen	92-100	ceramide synthase 2	Homo sapiens	19-24
24842017-4	2014	MTT assay showed PC-3M-2B4 cells exhibited a strong proliferation after transfection of LASS2/TMSG1-shRNA.LASS2/TMSG1-shRNA transfected clones demonstrated an increased clonogenicity by soft agar colony formation assay and a significant increase of tumor cell invasion by matrigel invasion study.Flow cytometry showed that after LASS2/TMSG1 gene silencing, the apoptotic rate of PC-3M-2B4 cell significantly decreased (P<0.01) without significant cell cycle change (P>0.05).Eight weeks after implantation into subcutaneous tissues in BAL B/c (nu+) mice, the size and weight of sh-LASS2/TMSG1 xenografts were significantly larger than those of the control group (P<0.05).Nuclear proliferation index of the subcutaneous tumor was also higher in the LASS2/TMSG1 shRNA group than those in the control group.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	88-93
24842017-4	2014	MTT assay showed PC-3M-2B4 cells exhibited a strong proliferation after transfection of LASS2/TMSG1-shRNA.LASS2/TMSG1-shRNA transfected clones demonstrated an increased clonogenicity by soft agar colony formation assay and a significant increase of tumor cell invasion by matrigel invasion study.Flow cytometry showed that after LASS2/TMSG1 gene silencing, the apoptotic rate of PC-3M-2B4 cell significantly decreased (P<0.01) without significant cell cycle change (P>0.05).Eight weeks after implantation into subcutaneous tissues in BAL B/c (nu+) mice, the size and weight of sh-LASS2/TMSG1 xenografts were significantly larger than those of the control group (P<0.05).Nuclear proliferation index of the subcutaneous tumor was also higher in the LASS2/TMSG1 shRNA group than those in the control group.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	94-99
24842017-4	2014	MTT assay showed PC-3M-2B4 cells exhibited a strong proliferation after transfection of LASS2/TMSG1-shRNA.LASS2/TMSG1-shRNA transfected clones demonstrated an increased clonogenicity by soft agar colony formation assay and a significant increase of tumor cell invasion by matrigel invasion study.Flow cytometry showed that after LASS2/TMSG1 gene silencing, the apoptotic rate of PC-3M-2B4 cell significantly decreased (P<0.01) without significant cell cycle change (P>0.05).Eight weeks after implantation into subcutaneous tissues in BAL B/c (nu+) mice, the size and weight of sh-LASS2/TMSG1 xenografts were significantly larger than those of the control group (P<0.05).Nuclear proliferation index of the subcutaneous tumor was also higher in the LASS2/TMSG1 shRNA group than those in the control group.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	106-111
24842017-4	2014	MTT assay showed PC-3M-2B4 cells exhibited a strong proliferation after transfection of LASS2/TMSG1-shRNA.LASS2/TMSG1-shRNA transfected clones demonstrated an increased clonogenicity by soft agar colony formation assay and a significant increase of tumor cell invasion by matrigel invasion study.Flow cytometry showed that after LASS2/TMSG1 gene silencing, the apoptotic rate of PC-3M-2B4 cell significantly decreased (P<0.01) without significant cell cycle change (P>0.05).Eight weeks after implantation into subcutaneous tissues in BAL B/c (nu+) mice, the size and weight of sh-LASS2/TMSG1 xenografts were significantly larger than those of the control group (P<0.05).Nuclear proliferation index of the subcutaneous tumor was also higher in the LASS2/TMSG1 shRNA group than those in the control group.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	112-117
24842017-4	2014	MTT assay showed PC-3M-2B4 cells exhibited a strong proliferation after transfection of LASS2/TMSG1-shRNA.LASS2/TMSG1-shRNA transfected clones demonstrated an increased clonogenicity by soft agar colony formation assay and a significant increase of tumor cell invasion by matrigel invasion study.Flow cytometry showed that after LASS2/TMSG1 gene silencing, the apoptotic rate of PC-3M-2B4 cell significantly decreased (P<0.01) without significant cell cycle change (P>0.05).Eight weeks after implantation into subcutaneous tissues in BAL B/c (nu+) mice, the size and weight of sh-LASS2/TMSG1 xenografts were significantly larger than those of the control group (P<0.05).Nuclear proliferation index of the subcutaneous tumor was also higher in the LASS2/TMSG1 shRNA group than those in the control group.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	106-111
24842017-4	2014	MTT assay showed PC-3M-2B4 cells exhibited a strong proliferation after transfection of LASS2/TMSG1-shRNA.LASS2/TMSG1-shRNA transfected clones demonstrated an increased clonogenicity by soft agar colony formation assay and a significant increase of tumor cell invasion by matrigel invasion study.Flow cytometry showed that after LASS2/TMSG1 gene silencing, the apoptotic rate of PC-3M-2B4 cell significantly decreased (P<0.01) without significant cell cycle change (P>0.05).Eight weeks after implantation into subcutaneous tissues in BAL B/c (nu+) mice, the size and weight of sh-LASS2/TMSG1 xenografts were significantly larger than those of the control group (P<0.05).Nuclear proliferation index of the subcutaneous tumor was also higher in the LASS2/TMSG1 shRNA group than those in the control group.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	112-117
24842017-4	2014	MTT assay showed PC-3M-2B4 cells exhibited a strong proliferation after transfection of LASS2/TMSG1-shRNA.LASS2/TMSG1-shRNA transfected clones demonstrated an increased clonogenicity by soft agar colony formation assay and a significant increase of tumor cell invasion by matrigel invasion study.Flow cytometry showed that after LASS2/TMSG1 gene silencing, the apoptotic rate of PC-3M-2B4 cell significantly decreased (P<0.01) without significant cell cycle change (P>0.05).Eight weeks after implantation into subcutaneous tissues in BAL B/c (nu+) mice, the size and weight of sh-LASS2/TMSG1 xenografts were significantly larger than those of the control group (P<0.05).Nuclear proliferation index of the subcutaneous tumor was also higher in the LASS2/TMSG1 shRNA group than those in the control group.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	112-117
24842017-4	2014	MTT assay showed PC-3M-2B4 cells exhibited a strong proliferation after transfection of LASS2/TMSG1-shRNA.LASS2/TMSG1-shRNA transfected clones demonstrated an increased clonogenicity by soft agar colony formation assay and a significant increase of tumor cell invasion by matrigel invasion study.Flow cytometry showed that after LASS2/TMSG1 gene silencing, the apoptotic rate of PC-3M-2B4 cell significantly decreased (P<0.01) without significant cell cycle change (P>0.05).Eight weeks after implantation into subcutaneous tissues in BAL B/c (nu+) mice, the size and weight of sh-LASS2/TMSG1 xenografts were significantly larger than those of the control group (P<0.05).Nuclear proliferation index of the subcutaneous tumor was also higher in the LASS2/TMSG1 shRNA group than those in the control group.	monooxyethylene trimethylolpropane tristearate	0-3	ceramide synthase 2	Homo sapiens	112-117
24842017-6	2014	V-ATPase activity, activities of secreted MMP-2 and MMP-9 and extracellular hydrogen ion concentration were significantly increased in LASS2/TMSG1-shRNA group compared with the control group (P<0.05).	Hydrogen	76-84	ceramide synthase 2	Homo sapiens	135-140
25356388-6	2014	Compared to parental controls, levels of CERS2 mRNA, protein, and activity were reduced by ~50% in fibroblasts isolated from this proband, resulting in significantly reduced levels of ceramides and sphingomyelins containing the very long-chain fatty acids C24:0 and C26:0.	Ceramides	184-193	ceramide synthase 2	Homo sapiens	41-46
25356388-6	2014	Compared to parental controls, levels of CERS2 mRNA, protein, and activity were reduced by ~50% in fibroblasts isolated from this proband, resulting in significantly reduced levels of ceramides and sphingomyelins containing the very long-chain fatty acids C24:0 and C26:0.	Sphingomyelins	198-212	ceramide synthase 2	Homo sapiens	41-46
25356388-6	2014	Compared to parental controls, levels of CERS2 mRNA, protein, and activity were reduced by ~50% in fibroblasts isolated from this proband, resulting in significantly reduced levels of ceramides and sphingomyelins containing the very long-chain fatty acids C24:0 and C26:0.	chain fatty acids	238-255	ceramide synthase 2	Homo sapiens	41-46
23538298-4	2013	Instead over-expression of CerS2 together with CerS4 or CerS6 increased the activity of CerS2 against very-long-chain ceramides about twofold.	Ceramides	118-127	ceramide synthase 2	Homo sapiens	27-32
23538298-4	2013	Instead over-expression of CerS2 together with CerS4 or CerS6 increased the activity of CerS2 against very-long-chain ceramides about twofold.	Ceramides	118-127	ceramide synthase 2	Homo sapiens	88-93
23538298-6	2013	Interestingly, down-regulation of ELOVL1 had a comprehensive effect on the synthesis of very long chain ceramides which possibly point to a requirement for ELOVL1 expression for full CerS2-activity.	Ceramides	104-113	ceramide synthase 2	Homo sapiens	183-188
23538298-7	2013	Co-expression of CerS2 with CerS4/CerS6 reversed the inhibitory effect of long chain ceramides on cell proliferation and the induction of apoptosis.	Ceramides	85-94	ceramide synthase 2	Homo sapiens	17-22
22580606-2	2013	Here, we found that LASS2 expression was significantly lower in drug-resistant Michigan Cancer Foundation-7/adriamycin (MCF-7/ADR) human breast cancer cells than the drug-sensitive MCF-7 cells, and low expression of LASS2 was associated with poor prognosis in patients with breast cancer.	Doxorubicin	108-118	ceramide synthase 2	Homo sapiens	20-25
22580606-3	2013	Our results showed that the overexpression of LASS2 in MCF-7/ADR cells increased the chemosensitivity to multiple chemotherapeutic agents, including doxorubicin (Dox), whereas LASS2 knockdown in MCF-7 cells decreased the chemosensitivity.	Doxorubicin	149-160	ceramide synthase 2	Homo sapiens	46-51
22580606-3	2013	Our results showed that the overexpression of LASS2 in MCF-7/ADR cells increased the chemosensitivity to multiple chemotherapeutic agents, including doxorubicin (Dox), whereas LASS2 knockdown in MCF-7 cells decreased the chemosensitivity.	Doxorubicin	162-165	ceramide synthase 2	Homo sapiens	46-51
22580606-4	2013	Cell-cycle analysis revealed a corresponding increase in apoptosis in the LASS2-overexpressing cells following Dox exposure, showing that the overexpression of LASS2 increased the susceptibility to Dox cytotoxicity.	Doxorubicin	111-114	ceramide synthase 2	Homo sapiens	74-79
22580606-4	2013	Cell-cycle analysis revealed a corresponding increase in apoptosis in the LASS2-overexpressing cells following Dox exposure, showing that the overexpression of LASS2 increased the susceptibility to Dox cytotoxicity.	Doxorubicin	111-114	ceramide synthase 2	Homo sapiens	160-165
22580606-4	2013	Cell-cycle analysis revealed a corresponding increase in apoptosis in the LASS2-overexpressing cells following Dox exposure, showing that the overexpression of LASS2 increased the susceptibility to Dox cytotoxicity.	Doxorubicin	198-201	ceramide synthase 2	Homo sapiens	74-79
22580606-4	2013	Cell-cycle analysis revealed a corresponding increase in apoptosis in the LASS2-overexpressing cells following Dox exposure, showing that the overexpression of LASS2 increased the susceptibility to Dox cytotoxicity.	Doxorubicin	198-201	ceramide synthase 2	Homo sapiens	160-165
22579584-4	2012	We demonstrate that knockdown of ELOVL1 or CERS2, which catalyze synthesis of C24 acyl-CoAs and C24 ceramide, respectively, drastically reduced C24 sphingolipid levels with a complementary increase in C16 sphingolipids.	Acyl Coenzyme A	82-91	ceramide synthase 2	Homo sapiens	43-48
22579584-4	2012	We demonstrate that knockdown of ELOVL1 or CERS2, which catalyze synthesis of C24 acyl-CoAs and C24 ceramide, respectively, drastically reduced C24 sphingolipid levels with a complementary increase in C16 sphingolipids.	Ceramides	100-108	ceramide synthase 2	Homo sapiens	43-48
22579584-4	2012	We demonstrate that knockdown of ELOVL1 or CERS2, which catalyze synthesis of C24 acyl-CoAs and C24 ceramide, respectively, drastically reduced C24 sphingolipid levels with a complementary increase in C16 sphingolipids.	Sphingolipids	148-160	ceramide synthase 2	Homo sapiens	43-48
22579584-4	2012	We demonstrate that knockdown of ELOVL1 or CERS2, which catalyze synthesis of C24 acyl-CoAs and C24 ceramide, respectively, drastically reduced C24 sphingolipid levels with a complementary increase in C16 sphingolipids.	Sphingolipids	205-218	ceramide synthase 2	Homo sapiens	43-48
22579584-5	2012	Under ELOVL1 or CERS2 knockdown conditions, cisplatin-induced apoptosis significantly increased.	Cisplatin	44-53	ceramide synthase 2	Homo sapiens	16-21
22579584-8	2012	Apoptosis induced by UV radiation or C6 ceramides also increased in ELOVL1 or CERS2 knockdown cells.	Ceramides	40-49	ceramide synthase 2	Homo sapiens	78-83
22573553-6	2012	The V-ATPase activity and extracellular hydrogen ion concentration were significantly increased in 2B4 cells transfected with the LASS2/TMSG1-siRNA compared with the controls.	Hydrogen	40-48	ceramide synthase 2	Homo sapiens	130-135
22573553-6	2012	The V-ATPase activity and extracellular hydrogen ion concentration were significantly increased in 2B4 cells transfected with the LASS2/TMSG1-siRNA compared with the controls.	Hydrogen	40-48	ceramide synthase 2	Homo sapiens	136-141
22573553-8	2012	Thus, we concluded that silencing of LASS2/TMSG1 may promote invasion of prostate cancer cell in vitro through increase of V-ATPase activity and extracellular hydrogen ion concentration and in turn the activation of secreted MMP-2.	Hydrogen	159-167	ceramide synthase 2	Homo sapiens	37-42
22573553-8	2012	Thus, we concluded that silencing of LASS2/TMSG1 may promote invasion of prostate cancer cell in vitro through increase of V-ATPase activity and extracellular hydrogen ion concentration and in turn the activation of secreted MMP-2.	Hydrogen	159-167	ceramide synthase 2	Homo sapiens	43-48
22230369-6	2012	To clarify the impact of this observation, we manipulated cellular ceramide levels by overexpressing ceramide synthases 2, 4 or 6 in MCF-7 (breast cancer) and HCT-116 (colon cancer) cells, respectively.	Ceramides	67-75	ceramide synthase 2	Homo sapiens	101-129
22178826-12	2011	CONCLUSION: Silencing of LASS2 can promote invasion of prostate cancer cells in vitro through the increase of the V-ATPases activity, extracellular hydrogen ion concentration and in turn the activation of secreted MMP-2, indicating that LASS2 is a novel tumor metastasis suppressor gene.	Hydrogen	148-156	ceramide synthase 2	Homo sapiens	25-30
21455605-11	2011	On the other hand, dasatinib downregulates expression levels of both GCS and SK-1 and upregulate apoptotic CerS2, -5 and -6 genes in Meg-01 cells.	Dasatinib	19-28	ceramide synthase 2	Homo sapiens	107-123
20940143-6	2011	For example, downregulation of CerS2 decreased very long-chain Cer but increased levels of CerS4, CerS5, and CerS6 expression and upregulated long-chain and medium-long-chain sphingolipids.	Sphingolipids	175-188	ceramide synthase 2	Homo sapiens	31-36
20937905-7	2010	We further established that ELOVL1 activity is regulated with the ceramide synthase CERS2, an enzyme essential for C24 sphingolipid synthesis.	Sphingolipids	119-131	ceramide synthase 2	Homo sapiens	84-89
20591223-2	2010	The inhibitory function of TMSG-1 in tumor cells may be related to vacuolar H+-ATPase and ceramide, but the underlying mechanism remains unknown.	Ceramides	90-98	ceramide synthase 2	Homo sapiens	27-33
20571735-5	2010	The effect of LASS2 gene on apoptosis was evaluated with Annexin-V/FITC and propidium iodide (PI) by flow cytometry.	Fluorescein-5-isothiocyanate	67-71	ceramide synthase 2	Homo sapiens	14-19
20571735-5	2010	The effect of LASS2 gene on apoptosis was evaluated with Annexin-V/FITC and propidium iodide (PI) by flow cytometry.	Propidium	76-92	ceramide synthase 2	Homo sapiens	14-19
19728861-0	2009	Disruption of ceramide synthesis by CerS2 down-regulation leads to autophagy and the unfolded protein response.	Ceramides	14-22	ceramide synthase 2	Homo sapiens	36-41
19728861-2	2009	CerS2 (ceramide synthase 2) is one of the six mammalian isoforms of ceramide synthase and is responsible for the synthesis of VLC (very-long-chain) ceramides, e.g. C24, C24:1.	Ceramides	148-157	ceramide synthase 2	Homo sapiens	0-5
19728861-2	2009	CerS2 (ceramide synthase 2) is one of the six mammalian isoforms of ceramide synthase and is responsible for the synthesis of VLC (very-long-chain) ceramides, e.g. C24, C24:1.	Ceramides	148-157	ceramide synthase 2	Homo sapiens	7-26
19728861-4	2009	CerS2 down-regulation had a broad effect on ceramide homoeostasis, not just on VLC ceramides.	Ceramides	44-52	ceramide synthase 2	Homo sapiens	0-5
19728861-4	2009	CerS2 down-regulation had a broad effect on ceramide homoeostasis, not just on VLC ceramides.	Ceramides	83-92	ceramide synthase 2	Homo sapiens	0-5
19728861-5	2009	Surprisingly, CerS2 down-regulation resulted in significantly increased LC (long-chain) ceramides, e.g. C14, C16, and our results suggested that the increase was due to a ceramide synthase-independent mechanism.	Ceramides	88-97	ceramide synthase 2	Homo sapiens	14-19
19728861-6	2009	CerS2-down-regulation-induced LC ceramide accumulation resulted in growth arrest which was not accompanied by apoptotic cell death.	Ceramides	33-41	ceramide synthase 2	Homo sapiens	0-5
19279183-6	2009	The augmentation of the various ceramides could be assigned to an increase of the messenger RNA levels of ceramide synthases (CerS) LASS2 (longevity assurance), LASS4 and LASS6.	Ceramides	32-41	ceramide synthase 2	Homo sapiens	132-137
19119142-6	2009	In vitro kinetic studies revealed that FTY720 is a competitive inhibitor of ceramide synthase 2 toward dihydrosphingosine with an apparent K(i) of 2.15 microm.	Fingolimod Hydrochloride	39-45	ceramide synthase 2	Homo sapiens	76-95
19119142-6	2009	In vitro kinetic studies revealed that FTY720 is a competitive inhibitor of ceramide synthase 2 toward dihydrosphingosine with an apparent K(i) of 2.15 microm.	safingol	103-121	ceramide synthase 2	Homo sapiens	76-95
18541923-9	2008	In HeLa cells overproducing the FA 2-hydroxylase FA2H, knock-down of CerS2 resulted in a reduction in total long-chain 2-hydroxy-CERs, confirming enzyme substrate specificity for chain length.	-cers	128-133	ceramide synthase 2	Homo sapiens	69-74
19024511-3	2008	Clones highly expressing TMSG-1 were identified by RT-PCR and Western Blot analysis after G418 screening.	antibiotic G 418	90-94	ceramide synthase 2	Homo sapiens	25-31
19024511-7	2008	Cell growth curve and MTT assay showed that TMSG-1 overexpression clones exhibited a strong inhibition of proliferation compared with that of the parental cells or those transfected with vector alone from the third day of culture (P <0.05).	monooxyethylene trimethylolpropane tristearate	22-25	ceramide synthase 2	Homo sapiens	44-50
18165233-0	2008	Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate.	sphingosine 1-phosphate	103-126	ceramide synthase 2	Homo sapiens	20-39
18165233-6	2008	CerS2 has a remarkable acyl-CoA specificity, showing no activity using C16:0-CoA and very low activity using C18:0, rather utilizing longer acyl-chain CoAs (C20-C26) for ceramide synthesis.	Ceramides	170-178	ceramide synthase 2	Homo sapiens	0-5
18165233-7	2008	There is a good correlation between CerS2 mRNA levels and levels of ceramide and sphingomyelin containing long acyl chains, at least in tissues where CerS2 mRNA is expressed at high levels.	Sphingomyelins	81-94	ceramide synthase 2	Homo sapiens	36-41
18165233-8	2008	Interestingly, the activity of CerS2 can be regulated by another bioactive sphingolipid, sphingosine 1-phosphate (S1P), via interaction of S1P with two residues that are part of an S1P receptor-like motif found only in CerS2.	Sphingolipids	75-87	ceramide synthase 2	Homo sapiens	31-36
18165233-8	2008	Interestingly, the activity of CerS2 can be regulated by another bioactive sphingolipid, sphingosine 1-phosphate (S1P), via interaction of S1P with two residues that are part of an S1P receptor-like motif found only in CerS2.	Sphingolipids	75-87	ceramide synthase 2	Homo sapiens	219-224
18165233-8	2008	Interestingly, the activity of CerS2 can be regulated by another bioactive sphingolipid, sphingosine 1-phosphate (S1P), via interaction of S1P with two residues that are part of an S1P receptor-like motif found only in CerS2.	sphingosine 1-phosphate	89-112	ceramide synthase 2	Homo sapiens	31-36
18165233-8	2008	Interestingly, the activity of CerS2 can be regulated by another bioactive sphingolipid, sphingosine 1-phosphate (S1P), via interaction of S1P with two residues that are part of an S1P receptor-like motif found only in CerS2.	sphingosine 1-phosphate	89-112	ceramide synthase 2	Homo sapiens	219-224
18194600-7	2007	Compared with the control cells, TMSG-1 overexpression MDA-MB-231 cells showed strong inhibition of proliferation and decreased clonogenicity in soft agar (P<0.05).	Agar	150-154	ceramide synthase 2	Homo sapiens	33-39
17308067-3	2007	Gemcitabine/doxorubicin combination treatment resulted in the elevation of mRNA and protein levels of LASS1 and not LASS2-6, which was consistent with a 3.5-fold increase in the endogenous (dihydro)ceramide synthase activity of LASS1 for the generation of C(18)-ceramide.	gemcitabine	0-11	ceramide synthase 2	Homo sapiens	116-123
17308067-3	2007	Gemcitabine/doxorubicin combination treatment resulted in the elevation of mRNA and protein levels of LASS1 and not LASS2-6, which was consistent with a 3.5-fold increase in the endogenous (dihydro)ceramide synthase activity of LASS1 for the generation of C(18)-ceramide.	Doxorubicin	12-23	ceramide synthase 2	Homo sapiens	116-123
15823095-5	2005	Overproduction of Lass1 increased C18:0-ceramide levels preferentially, and overproduction of Lass2 and Lass4 increased levels of longer ceramides such as C22:0- and C24:0-ceramides.	Ceramides	137-146	ceramide synthase 2	Homo sapiens	94-99
15823095-5	2005	Overproduction of Lass1 increased C18:0-ceramide levels preferentially, and overproduction of Lass2 and Lass4 increased levels of longer ceramides such as C22:0- and C24:0-ceramides.	Ceramides	172-181	ceramide synthase 2	Homo sapiens	94-99
15823095-9	2005	Of the five members, only Lass2, Lass5 and Lass6 were N-glycosylated, each at their N-terminal Asn residue.	Nitrogen	54-55	ceramide synthase 2	Homo sapiens	26-31
15823095-9	2005	Of the five members, only Lass2, Lass5 and Lass6 were N-glycosylated, each at their N-terminal Asn residue.	Asparagine	95-98	ceramide synthase 2	Homo sapiens	26-31
15796876-2	2005	METHODS: A dominant epitope-TMSG-1(15)-derived from TMSG-1 was synthesized based on Fmoc method, and the hapten was conjugated to Imject Maleimide activated mcKLH as a carrier protein.	maleimide	137-146	ceramide synthase 2	Homo sapiens	28-34
15796876-2	2005	METHODS: A dominant epitope-TMSG-1(15)-derived from TMSG-1 was synthesized based on Fmoc method, and the hapten was conjugated to Imject Maleimide activated mcKLH as a carrier protein.	maleimide	137-146	ceramide synthase 2	Homo sapiens	52-58
15672611-2	2004	A dominant epitope, TMSG-1(15)--derived from TMSG-1--was automatically synthesized based on the Fmoc method, and the hapten was conjugated to Imject Maleimide activated mcKLH as a carrier protein.	maleimide	149-158	ceramide synthase 2	Homo sapiens	20-26
15672611-2	2004	A dominant epitope, TMSG-1(15)--derived from TMSG-1--was automatically synthesized based on the Fmoc method, and the hapten was conjugated to Imject Maleimide activated mcKLH as a carrier protein.	maleimide	149-158	ceramide synthase 2	Homo sapiens	45-51
12920802-3	2003	Both sense and antisense eukaryotic expression plasmids of TMSG-1 gene were transfected into the highly metastatic subclone PG-BE1 by LipofectAMINE method and the positive clones were selected by G418.	pg-be1	124-130	ceramide synthase 2	Homo sapiens	59-65
12920802-3	2003	Both sense and antisense eukaryotic expression plasmids of TMSG-1 gene were transfected into the highly metastatic subclone PG-BE1 by LipofectAMINE method and the positive clones were selected by G418.	Lipofectamine	134-147	ceramide synthase 2	Homo sapiens	59-65
15969039-4	2003	SDS-PAGE analysis revealed that the molecular weight of expressed product of LASS2 was about 28 kD.	Sodium Dodecyl Sulfate	0-3	ceramide synthase 2	Homo sapiens	77-82
15969039-6	2003	This recombinant LASS2 protein was purified by metal affinity resin and the purity is above 90%.	Metals	47-52	ceramide synthase 2	Homo sapiens	17-22